Last reviewed 2026-05-28 · How we verify

UCB4940 560 mg

UCB Celltech · Phase 1 active Small molecule ✓ Verified May 2026 Quality 0/100

UCB4940 560 mg is a Small molecule drug developed by UCB Celltech. It is currently in Phase 1 development.

UCB4940 is a small molecule with the synonyms MRK-560 and MRK_560. It has been studied in a clinical trial for the treatment of Psoriatic Arthritis, with doses of 40 mg, 80 mg, and 160 mg being investigated.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	UCB4940 560 mg
Sponsor	UCB Celltech
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

UCB4940 560 mg CI brief — competitive landscape report
UCB4940 560 mg updates RSS · CI watch RSS
UCB Celltech portfolio CI

Frequently asked questions about UCB4940 560 mg

What is UCB4940 560 mg?

UCB4940 560 mg is a Small molecule drug developed by UCB Celltech.

Who makes UCB4940 560 mg?

UCB4940 560 mg is developed by UCB Celltech (see full UCB Celltech pipeline at /company/ucb-celltech).

What development phase is UCB4940 560 mg in?

UCB4940 560 mg is in Phase 1.

Manufacturer: UCB Celltech — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing